WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Accounts Payable & Accrued Expense : $473 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Accounts Payable & Accrued Expense?

WuXi Biologics (Cayman)'s quarterly accounts payable & accrued expense declined from Dec. 2022 ($580 Mil) to Jun. 2023 ($304 Mil) but then increased from Jun. 2023 ($304 Mil) to Dec. 2023 ($473 Mil).

WuXi Biologics (Cayman)'s annual accounts payable & accrued expense declined from Dec. 2021 ($668 Mil) to Dec. 2022 ($580 Mil) and declined from Dec. 2022 ($580 Mil) to Dec. 2023 ($473 Mil).

WuXi Biologics (Cayman) Accounts Payable & Accrued Expense Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Accounts Payable & Accrued Expense Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

220.72

455.62

668.13

579.92

472.63

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial													668.13	528.44	579.92	303.57	472.63

WuXi Biologics (Cayman) Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.